In the following video, Fool contributor Maxx Chatsko explains whether he thinks Celgene or Biogen is the better buy. The companies have tracked one another in valuation, separated by as little as half of one percentage point. Additionally, both have promising pipelines that have kept investors' expectations high. Does one stand out? Is it too close to call? Watch the video below to find out. If you are eyeing either company -- or both -- then you may want to use the recent pullbacks as a buying opportunity.
Taking a break from the volatile biotech sector? Looking for ways to diversify into dividend-paying stocks? The Motley Fool's special report "Secure Your Future With 9 Rock-Solid Dividend Stocks" is a great way to kick-start your search. Just click here to get your free copy today.
The article Better Buy: Celgene or Biogen? originally appeared on Fool.com.Fool contributor Maxx Chatsko has no position in any stocks mentioned. Check out his personal portfolio, his CAPS page, or follow him on Twitter @BlacknGoldFool to keep up with his writing on energy, bioprocessing, and biotechnology. The Motley Fool recommends Celgene. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.